PTAB rejects Vimovo IPR trial
The Patent Trial and Appeal Board (PTAB) has rejected the Coalition for Affordable Drugs' attempt to invalidate a patent covering Pozen’s Vimovo (naproxen and esomeprazole magnesium) drug.
Administrative patent judge Toni Scheiner wrote on Tuesday, December 8, that the coalition had failed to show a “reasonable likelihood that it would prevail in its challenges” against the patent, US number 6,926,907.
The coalition, in an inter partes review (IPR) filed in May, argued that the patent was obvious.
Vimovo, used to treat arthritis, is marketed by Horizon Pharma. Pozen, which has a marketing deal with Horizon, obtained the rights to sell the drug from AstraZeneca in 2013.
Another petition ch allenging another patent, US number 8,858,996, which also covers the Vimovo drug and owned by Pozen, was filed in July.
The PTAB has yet to decide on whether it will institute the IPR.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk